-
1
GLP-1 receptor agonists revolutionize diabetes and obesity treatment.
-
2
Cutting-edge mass spectrometry methods track drug levels in patients.
-
3
Innovation in peptide design is driven by the success of GLP-1 drugs.
-
4
Challenges include impurity profiling and structural characterization.
-
5
Best practices for GLP-1 peptide analysis are evolving in the field.
-
6
Analytical science is crucial for developing and regulating GLP-1 therapies.
-
7
Expert insights highlight the rapid changes in the landscape.
Original Source(s)
Related Content
GLP-1 Analysis: Riding the Wave of Peptide Innovation
The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.
April 9, 2026
-
18 min
The Missing Piece in the Dark Metabolome Puzzle?
Microdroplets formed during electrospray ionization may trigger chemical reactions that help explain a substantial portion of the “dark metabolome” – though some researchers question their relevance under typical metabolomics conditions
April 8, 2026
-
12 min
Wegovy and Possible Vision Risk
Higher dose weight loss injectable demonstrates nearly five times higher ischaemic optic neuropathy risk than other semaglutide GLP-1 agonists
April 8, 2026
-
3 min
